% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Lodde:275221,
      author       = {G. C. Lodde and F. Krefting and J.-M. Placke and L.
                      Schneider and M. Fiedler and U. Dittmer and J. Becker$^*$
                      and S. Hölsken and D. Schadendorf$^*$ and S. Ugurel$^*$ and
                      W. Sondermann},
      title        = {{COVID}-19 vaccination in psoriasis patients receiving
                      systemic treatment: {A} prospective single-center study.},
      journal      = {Frontiers in immunology},
      volume       = {14},
      issn         = {1664-3224},
      address      = {Lausanne},
      publisher    = {Frontiers Media},
      reportid     = {DKFZ-2023-00679},
      pages        = {1107438},
      year         = {2023},
      abstract     = {The rate of seroconversion after COVID-19 vaccination in
                      patients with moderate to severe psoriasis requiring
                      systemic treatment is poorly understood.The aim of this
                      prospective single-center cohort study performed between May
                      2020 and October 2021 was to determine the rate of
                      seroconversion after COVID-19 vaccination in patients under
                      active systemic treatment for moderate to severe
                      psoriasis.Inclusion criteria were systemic treatment for
                      moderate to severe psoriasis, known COVID-19 vaccination
                      status, and repetitive anti-SARS-CoV-2-S IgG serum
                      quantification. The primary outcome was the rate of
                      anti-SARS-CoV-2-S IgG seroconversion after complete COVID-19
                      vaccination.77 patients with a median age of 55.9 years
                      undergoing systemic treatment for moderate to severe
                      psoriasis were included. The majority of patients received
                      interleukin- (n=50, $64.9\%)$ or tumor necrosis factor
                      (TNF)-α inhibitors (n=16, $20.8\%)$ as systemic treatment
                      for psoriasis; nine patients $(11.7\%)$ were treated with
                      methotrexate (MTX) monotherapy, and one patient each
                      received dimethyl fumarate $(1.3\%),$ respectively
                      apremilast $(1.3\%).$ All included patients completed
                      COVID-19 vaccination with two doses over the course of the
                      study. Serum testing revealed that 74 patients $(96.1\%)$
                      showed an anti-SARS-CoV-2-S IgG seroconversion. While all
                      patients on IL-17A, -12 or -12/23 inhibitors (n=50) achieved
                      seroconversion, three of 16 patients $(18.8\%)$ receiving
                      MTX and/or a TNF-α inhibitor as main anti-psoriatic
                      treatment did not. At follow-up, none of the patients had
                      developed symptomatic COVID-19 or died from
                      COVID-19.Anti-SARS-CoV-2-S IgG seroconversion rates
                      following COVID-19 vaccination in psoriasis patients under
                      systemic treatment were high. An impaired serological
                      response, however, was observed in patients receiving MTX
                      and/or TNF-α inhibitors, in particular infliximab.},
      keywords     = {COVID-19 vaccines (Other) / biologics (Other) / psoriasis
                      (Other) / psoriasis treatment (Other) / seroconversion
                      (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37006279},
      pmc          = {pmc:PMC10061348},
      doi          = {10.3389/fimmu.2023.1107438},
      url          = {https://inrepo02.dkfz.de/record/275221},
}